Exploring High Growth Tech Stocks In Switzerland October 2024

The Switzerland market experienced a modest decline recently, as the benchmark SMI ended down 0.33% amid investor anticipation of the European Central Bank's upcoming monetary policy announcement and digestion of regional economic data. In this fluctuating environment, identifying high growth tech stocks requires careful consideration of their resilience to market volatility and potential for innovation-driven expansion within the dynamic Swiss economy.

Top 10 High Growth Tech Companies In Switzerland

Name	Revenue Growth	Earnings Growth	Growth Rating
LEM Holding	8.81%	20.48%	★★★★★☆
Santhera Pharmaceuticals Holding	24.55%	35.40%	★★★★★★
ALSO Holding	12.58%	26.76%	★★★★☆☆
Comet Holding	19.66%	47.84%	★★★★★☆
SoftwareONE Holding	8.59%	52.33%	★★★★★☆
Cicor Technologies	6.78%	27.14%	★★★★☆☆
Addex Therapeutics	26.51%	33.31%	★★★★★☆
Basilea Pharmaceutica	9.24%	33.25%	★★★★★☆
Sensirion Holding	13.86%	102.68%	★★★★☆☆
MCH Group	4.41%	100.62%	★★★★☆☆

Click here to see the full list of 12 stocks from our SIX Swiss Exchange High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

ALSO Holding (SWX:ALSN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ALSO Holding AG is a technology services provider for the ICT industry, operating in Switzerland, Germany, the Netherlands, Poland, and internationally with a market capitalization of CHF3.20 billion.

Operations: ALSO Holding AG generates revenue primarily from its operations in Central Europe (€4.62 billion) and Northern/Eastern Europe (€5.24 billion). The company focuses on providing technology services within the ICT industry across several international markets.

ALSO Holding, navigating through a challenging tech landscape, reported a dip in half-year sales to EUR 4.28 billion from EUR 4.83 billion year-over-year, with net income also decreasing to EUR 41.66 million from EUR 52.53 million. Despite this downturn, the company's future looks promising with expected revenue and earnings growth at 12.6% and 26.8% per year respectively—outpacing the Swiss market projections of 4.3% and 11.6%. This growth is underpinned by significant R&D investments aimed at driving innovation and maintaining competitive edge in high-demand tech sectors like cloud computing and cybersecurity solutions—critical areas as businesses increasingly shift towards digital operations.

• Navigate through the intricacies of ALSO Holding with our comprehensive health report here.

• Review our historical performance report to gain insights into ALSO Holding's's past performance.

Basilea Pharmaceutica (SWX:BSLN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in developing products for oncology and anti-infectives, with a market cap of CHF548.48 million.

Operations: The company generates revenue primarily from the discovery, development, and commercialization of innovative pharmaceutical products, amounting to CHF149.02 million. It operates within the therapeutic areas of oncology and anti-infectives.

Basilea Pharmaceutica, amidst a challenging biotech landscape, has revised its 2024 financial outlook upwards, now expecting CHF 203 million in revenue and a net profit of CHF 60 million. This optimistic revision follows significant regulatory approvals such as the EC’s extension for Cresemba® to pediatric patients, enhancing its market exclusivity until October 2027—a strategic win that could bolster long-term revenues. Despite recent earnings showing a dip with half-year revenue down to CHF 76.29 million from CHF 84.91 million year-over-year, Basilea's commitment to innovation is evident with R&D expenses earmarked at robust levels aimed at driving future growth in high-stakes markets like invasive fungal infections treatments. With earnings projected to surge by an impressive annual rate of 33.2%, Basilea is strategically positioning itself for profitability and market leadership within the biotech sector.

• Unlock comprehensive insights into our analysis of Basilea Pharmaceutica stock in this health report.

• Learn about Basilea Pharmaceutica's historical performance.

Temenos (SWX:TEMN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Temenos AG develops, markets, and sells integrated banking software systems to financial institutions globally, with a market capitalization of CHF4.65 billion.

Operations: The company generates revenue primarily from two segments: Product, contributing $879.99 million, and Services, adding $132.98 million.

Temenos, a Swiss tech firm, is navigating the competitive landscape with strategic executive appointments and share buybacks. Recently, the company repurchased shares worth CHF 200 million, enhancing shareholder value. With revenue hitting USD 248.39 million this quarter, up from USD 238.97 million last year, and a slight dip in net income to USD 37.06 million from USD 38.31 million, Temenos remains resilient amidst market fluctuations. The appointment of Barb Morgan as Chief Product and Technology Officer underscores its commitment to integrating AI in banking solutions—a move poised to expand its global footprint significantly through advanced cloud-based platforms and AI-driven solutions for financial institutions.

• Dive into the specifics of Temenos here with our thorough health report.

• Gain insights into Temenos' historical performance by reviewing our past performance report.

Seize The Opportunity

• Get an in-depth perspective on all 12 SIX Swiss Exchange High Growth Tech and AI Stocks by using our screener here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com